Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

Rhea-AI Summary

Passage Bio (NASDAQ: PASG) will host a conference call on August 4, 2022, at 8:30 a.m. ET to discuss its Q2 2022 financial results and business updates. The call aims to provide insights into the company's advancements in developing gene therapies for central nervous system (CNS) disorders, including GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia. Passage Bio has established collaborations with the University of Pennsylvania's Gene Therapy Program to enhance its clinical pipeline. An archived webcast will be available following the event.

Positive

• Upcoming conference call to discuss Q2 2022 financial results.
• Advancing three clinical programs targeting CNS disorders.
• Strategic collaboration with the University of Pennsylvania enhances access to gene therapy innovations.

Negative

• None.

PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results and discuss recent business highlights.

To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Passage Bio Investors:

Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com 

Passage Bio Media:

Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
MikeBeyer@sambrown.com 

FAQ

What is the date of Passage Bio's Q2 2022 financial results conference call?

The conference call is scheduled for August 4, 2022.

What will Passage Bio discuss in the conference call?

The company will report its Q2 2022 financial results and recent business highlights.

What are the main clinical programs of Passage Bio?

Passage Bio is focusing on GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia.

How can I access the webcast of the conference call?

The archived webcast will be available on Passage Bio's website approximately two hours after the event.